(Photo courtesy: www.biosimilarnews.com)
Pfizer has announced that the company has been granted approval from the Canadian Competition Bureau with respect to its pending acquisition of Hospira. As part of its agreement with the Canadian Competition Bureau, Pfizer has committed to divest certain assets in Canada.
"We are pleased the Canadian Competition Bureau concluded its review of the transaction and approved the pending combination of Pfizer and Hospira. We continue to work cooperatively with the regulatory agencies to obtain the requisite approvals, and continue to expect the transaction to close in the second half of 2015," said Mr Ian Read, chairman and chief executive officer, Pfizer.
Completion of the transaction remains subject to governmental and regulatory approvals in certain other jurisdictions and other usual and customary closing conditions.